Phaseline

Targets › ARAF

ARAF (Serine/threonine-protein kinase A-Raf): drug programs, companies and trials

4 programs from 4 companies in 9 trials: 5 Phase 2, 3 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.

Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May also regulate the TOR signaling cascade. (UniProt, P10398)

Open in Phaseline: the race on ARAF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Day One BiopharmaceuticalsTovorafenib
RAF serine/threonine protein kinase inhibitor
RAF1, BRAF, ARAFPhase 3Low-grade Glioma; Craniopharyngioma, Child; Recurrent Langerhans Cell Histiocytosis; Hairy Cell LeukemiaMay 2027
Hanmi Pharmaceutical CompanyBelvarafenib
RAF serine/threonine protein kinase inhibitor
RAF1, BRAF, ARAFPhase 2Advanced or Metastatic MelanomaSep 2029
RocheBelvarafenib
RAF serine/threonine protein kinase inhibitor
RAF1, BRAF, ARAFPhase 1Melanoma; Primary Brain TumorDec 2026
IpsenTovorafenib
RAF serine/threonine protein kinase inhibitor
RAF1, BRAF, ARAFPhase 1Low-grade GliomaJul 2030

Conditions

Low-grade Glioma (3) Melanoma (1) Primary Brain Tumor (1) Craniopharyngioma, Child (1) Recurrent Langerhans Cell Histiocytosis (1) Hairy Cell Leukemia (1) Advanced or Metastatic Melanoma (1)

Modalities

small molecule (3), mixed (1)

Companies

Roche (1) Day One Biopharmaceuticals (1) Ipsen (1) Hanmi Pharmaceutical Company (1)

Related targets

RAF1 (4) BRAF (4)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.